BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Choe WH, Kim K, Lee SY, Choi YM, Kwon SY, Kim JH, Kim BJ. Tenofovir is a more suitable treatment than entecavir for chronic hepatitis B patients carrying naturally occurring rtM204I mutations. World J Gastroenterol 2019; 25(33): 4985-4998 [PMID: 31543688 DOI: 10.3748/wjg.v25.i33.4985]
URL: https://www.wjgnet.com/1007-9327/full/v25/i33/4985.htm
Number Citing Articles
Manas K. Behera, Girish K. Pati, Jimmy Narayan, Debakanta Mishra, Lalit K. Meher, Ayaskant Singh, Kanishka Uthansingh, Manoj K. Sahu. Tenofovir is Superior to Entecavir in Patients with Treatment-naïve Hepatitis B e-Antigen–Positive Chronic Hepatitis BJournal of Clinical and Experimental Hepatology 2021; 11(1): 37 doi: 10.1016/j.jceh.2020.05.003